These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20308443)

  • 21. Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.
    Abraham J; Robidoux A; Tan AR; Limentani S; Sturtz K; Shalaby I; Alcorn H; Buyse ME; Wolmark N; Jacobs SA
    Breast Cancer Res Treat; 2015 Jul; 152(2):399-405. PubMed ID: 26126970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy-induced irreversible alopecia in early breast cancer patients.
    Kim GM; Kim S; Park HS; Kim JY; Nam S; Park S; Kim SI; Kim D; Sohn J
    Breast Cancer Res Treat; 2017 Jun; 163(3):527-533. PubMed ID: 28324267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment.
    Fatayer H; Sharma N; Manuel D; Kim B; Keding A; Perren T; Velikova G; Lansdown M; Shaaban AM; Dall B
    Eur J Surg Oncol; 2016 Jul; 42(7):965-72. PubMed ID: 27260848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy of breast cancer.
    Garces CA; Cance WG
    Am Surg; 2004 Jul; 70(7):565-9. PubMed ID: 15279176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
    Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
    Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LONG-TERM RESULTS OF COMBINATION THERAPY FOR LOCALLY ADVANCED BREAST CANCER.
    Zhumakayeva A; Rakhimov K; Sirota V; Arystan L; Madiyarov A; Adekenov S
    Georgian Med News; 2018 Sep; (282):30-35. PubMed ID: 30358536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
    Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
    Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
    Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
    BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
    Denis F; Desbiez-Bourcier AV; Chapiron C; Arbion F; Body G; Brunereau L
    Eur J Surg Oncol; 2004 Dec; 30(10):1069-76. PubMed ID: 15522553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.
    O'Regan RM; Von Roenn JH; Carlson RW; Malik U; Sparano JA; Staradub V; Khan S; Jovanovic B; Morrow M; Gradishar WJ
    Clin Breast Cancer; 2005 Jun; 6(2):163-8. PubMed ID: 16001995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim TH; Kang DK; Yim H; Jung YS; Kim KS; Kang SY
    J Comput Assist Tomogr; 2012; 36(2):200-6. PubMed ID: 22446360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.
    Yi A; Cho N; Im SA; Chang JM; Kim SJ; Moon HG; Han W; Park IA; Noh DY; Moon WK
    Radiology; 2013 Sep; 268(3):662-72. PubMed ID: 23592770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
    Evans TR; Yellowlees A; Foster E; Earl H; Cameron DA; Hutcheon AW; Coleman RE; Perren T; Gallagher CJ; Quigley M; Crown J; Jones AL; Highley M; Leonard RC; Mansi JL
    J Clin Oncol; 2005 May; 23(13):2988-95. PubMed ID: 15860854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
    Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
    Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
    Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
    Partridge SC; Gibbs JE; Lu Y; Esserman LJ; Tripathy D; Wolverton DS; Rugo HS; Hwang ES; Ewing CA; Hylton NM
    AJR Am J Roentgenol; 2005 Jun; 184(6):1774-81. PubMed ID: 15908529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.